Literature DB >> 26150164

Polyclonal neural cell adhesion molecule antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength.

Yan Guo1, Lizhen Pan1, Wuchao Liu1, Yougui Pan1, Zhiyu Nie2, Lingjing Jin3.   

Abstract

This study aimed to investigate if the effective duration time of botulinum toxin A (Btx-A) could be prolonged by polyclonal neural cell adhesion molecule antibody (P-NCAM-Ab). 175 male SD rats were randomly divided into three major groups: control group (n = 25), Btx-A group (n = 25), and P-NCAM-Ab groups. P-NCAM-Ab groups were composed of five sub-groups, with 25 rats each in the dose-response study. Muscle strength of rat lower limbs was determined using a survey system. The expressions of muscle-specific receptor tyrosine kinase (MuSK) and neural cell adhesion molecule (NCAM) were determined by real-time polymerase chain reactions (RT-PCR) and western blotting (WB). The muscle strength was significantly decreased by Btx-A in Btx-A/P-NCAM-Ab groups compared with normal control group. Besides, the muscle strength of P-NCAM-Ab group was significantly decreased compared with the Btx-A group. The recovery time of muscle strength in P-NCAM-Ab group was significantly longer compared with Btx-A group. RT-PCR and WB assay showed that PNCAM-Ab delayed the increase of MuSK and NCAM after Btx-A injection. P-NCAM-Ab prolongs the effective duration time of Btx-A in decreasing muscle strength, which could provide a novel enhancement in clinical application.

Entities:  

Keywords:  Botulinum toxin A; Muscle strength; Muscle-specific kinase; Neural cell adhesion molecule; Polyclonal neural cell adhesion molecule antibody

Mesh:

Substances:

Year:  2015        PMID: 26150164     DOI: 10.1007/s10072-015-2291-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  30 in total

1.  An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia.

Authors:  Robert Chinnapongse; Eric J Pappert; Marian Evatt; Alan Freeman; William Birmingham
Journal:  Int J Neurosci       Date:  2010-11       Impact factor: 2.292

2.  Botulinum toxin: from spasticity reliever to a neuromotor re-learning tool.

Authors:  R V Krishnan
Journal:  Int J Neurosci       Date:  2005-10       Impact factor: 2.292

Review 3.  Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration.

Authors:  Patricia F Maness; Melitta Schachner
Journal:  Nat Neurosci       Date:  2007-01       Impact factor: 24.884

Review 4.  [Clinical relevance of botulinum toxin antibodies].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

5.  Polyclonal antibodies against NCAM reduce paralysis-induced axonal sprouting.

Authors:  R Schäfer; A Wernig
Journal:  J Neurocytol       Date:  1998-08

6.  A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis, enhances presynaptic function, and facilitates memory consolidation.

Authors:  Karine Cambon; Stine M Hansen; Cesar Venero; A Isabel Herrero; Galina Skibo; Vladimir Berezin; Elisabeth Bock; Carmen Sandi
Journal:  J Neurosci       Date:  2004-04-28       Impact factor: 6.167

7.  Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg.

Authors:  Luca Carli; Cesare Montecucco; Ornella Rossetto
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

8.  Is electrical stimulation beneficial for improving the paralytic effect of botulinum toxin type A in children with spastic diplegic cerebral palsy?

Authors:  Dong-wook Rha; Eun Joo Yang; Ho Ik Chung; Hyoung Bin Kim; Chang-il Park; Eun Sook Park
Journal:  Yonsei Med J       Date:  2008-08-30       Impact factor: 2.759

Review 9.  Cytokines, growth factors and sprouting at the neuromuscular junction.

Authors:  Arthur W English
Journal:  J Neurocytol       Date:  2003 Jun-Sep

10.  High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference?

Authors:  Michael H Boyle; Gerald McGwin; Courtney E Flanagan; Matthew G Vicinanzo; John A Long
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2009 Mar-Apr       Impact factor: 1.746

View more
  3 in total

1.  Dynamic muscle paralytic effects of a novel botulinum toxin A free of neurotoxin-associated proteins.

Authors:  Wu-Chao Liu; Jun-Hui Su; Ya Feng; Xue-Rui Xiang; Li-Zhen Pan; Ying Liu; Lin Ma; Zhi-Yu Nie; Xue-Ping Zhang; Ling-Jing Jin
Journal:  Pharmacol Res Perspect       Date:  2022-06

2.  Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats.

Authors:  Ya Feng; Wuchao Liu; Lizhen Pan; Cong Jiang; Chengxi Zhang; Yuxuan Lu; Zhiyu Nie; Lingjing Jin
Journal:  Drug Des Devel Ther       Date:  2017-06-28       Impact factor: 4.162

3.  Agrin Influences Botulinum Neurotoxin A-Induced Nerve Sprouting via miR-144-agrin-MuSK Signaling.

Authors:  Lin Ma; Lizhen Pan; Wuchao Liu; Ying Liu; Xuerui Xiang; Yougui Pan; Xiaolong Zhang; Lingjing Jin
Journal:  Front Cell Dev Biol       Date:  2020-01-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.